Harvard Bioscience price target lowered to $2 from $3 at Benchmark

Benchmark analyst Bruce Jackson lowered the firm’s price target on Harvard Bioscience (HBIO) to $2 from $3 and keeps a Speculative Buy rating on the shares. Concerns about basic research funding, drug pricing, and tariffs create an uncertain environment for the sector that seems likely to persist for the near future, says the analyst, who cites the heightened risk profile for the firm’s lowered target.